• ICOS–Th2 Signaling in Allergic Rhinitis

  2026-08-22

  The reference study links inducible co-stimulator (ICOS) signaling to T-cell imbalance in allergic rhinitis, with particular emphasis on Th2 differentiation and symptom severity. Its combination of immune profiling, longitudinal subcutaneous immunotherapy follow-up, and pathway inhibition provides a useful framework for evaluating ICOS-expressing Th2 cells as biomarkers and therapeutic targets.

• BRCAness and Olaparib Sensitivity in Mesothelioma

  2026-08-22

  Borchert et al. connected homologous recombination repair gene-expression patterns with olaparib response in malignant pleural mesothelioma models. Their results support BRCAness-based stratification, particularly in BAP1-altered tumors, while emphasizing that the proposed olaparib–cisplatin strategy remains an in vitro, hypothesis-generating approach.

• Dextrose (D-Glucose) in Hypoxia-Driven Immunometabolism

  2026-08-21

  Dextrose is more than a routine media ingredient: it is a controllable experimental variable for studying nutrient competition, glycolytic adaptation, and immune function in hypoxic tumor models. This article connects the mechanistic framework of hypoxia and immunometabolism with practical assay design, product-selection criteria, and translational strategy. It also explains how Dextrose (D-glucose) from APExBIO can support reproducible glucose metabolism research while highlighting the limitations that separate a well-controlled in vitro model from a clinical conclusion.

• Protease Inhibitor Cocktail EDTA-Free: K1007 Guide

  2026-08-20

  Protease Inhibitor Cocktail EDTA-Free K1007 is a 100X DMSO formulation for broad protease control during protein extraction. Its EDTA-free design supports workflows in which divalent cations must remain available, including phosphorylation analysis and kinase assays.

• Pentoxifylline Modulates Neonatal LPS Hyperinflammation

  2026-08-20

  The reference study examined how Pentoxifylline alters LPS-triggered monocyte responses in preterm and term infants compared with adults. Its main innovation was integrating surface-marker profiling, cytokine analysis, phagocytosis, and TLR4 measurements to show strong anti-inflammatory activity alongside age-dependent effects on innate immune function.

• CH 223191: AhR Antagonist for Toxicology

  2026-08-19

  CH 223191 is an aryl hydrocarbon receptor antagonist that blocks TCDD-induced transcriptional activation with an IC50 of approximately 30 nM in cell-based assays. It is a practical AhR signaling pathway inhibitor for dioxin toxicity mechanism study, hepatic CYP1A1 research, and mechanistic environmental toxicology research.

• ATG9A, PTOV1, and 14-3-3 Cancer Mechanisms

  2026-08-19

  The reference study identifies ATG9A and PTOV1 as previously unrecognized 14-3-3-interacting proteins and defines distinct regulatory mechanisms linking them to autophagy, protein stability, and oncogenic signaling. Its combined proximity-labeling, proteomic, and biochemical strategy provides a framework for studying phospho-dependent protein interactions in cancer biology.

• Alternative AGL18-1 Splicing Controls Mustard Flowering

  2026-08-18

  A 2025 study identifies alternative splicing of BjuAGL18-1 as a photoperiod-responsive switch that produces opposing effects on flowering in Brassica juncea. Full-length BjuAGL18-1L represses floral transition through corepressor and histone deacetylase interactions, whereas the truncated BjuAGL18-1S isoform forms inhibitory heterodimers and accelerates flowering.

• 2X Taq PCR Master Mix for C. elegans Assays

  2026-08-18

  Learn how 2X Taq PCR Master Mix supports a mechanistic assay strategy for studying pheromone-dependent neurodegeneration in C. elegans. This guide connects Taq chemistry, genotype verification, TA cloning, and the causal findings of a Cell Reports study without overstating what endpoint PCR can prove.

• BQCA: Selective M1 Receptor Potentiation

  2026-08-17

  Benzyl Quinolone Carboxylic Acid (BQCA) is a selective positive allosteric modulator that enhances acetylcholine receptor signaling through M1 muscarinic receptors. Product data and a 2025 BRET study support its use for mechanistic research in cognitive function modulation, neuronal activity, and Alzheimer's disease research, while distinguishing cellular signaling from therapeutic efficacy.

• FITC Goat Anti-Rabbit IgG (H+L) Antibody Workflow

  2026-08-17

  Build sensitive fluorescence workflows for rabbit primary antibodies in intestinal barrier, inflammation, and signaling studies. This fluorescein-conjugated secondary antibody supports microscopy, immunofluorescence assays, and flow cytometry while offering practical controls for separating biological signal from background.

• D-Luciferin Potassium Salt: From Signal to Strategy

  2026-08-16

  A translational framework for using D-Luciferin potassium salt to improve longitudinal tumor cell tracking, interpret luciferase signals mechanistically, and strengthen preclinical oncology decisions.

• RHEB Neddylation, mTORC1, and Liver Tumorigenesis

  2026-08-15

  The reference study identifies RHEB as a non-cullin substrate of the UBE2F–SAG neddylation pathway and shows that modification at K169 strengthens RHEB localization and activity toward mTORC1. Cellular, liver-specific genetic, and patient-correlation data connect this mechanism with steatosis and hepatocellular carcinoma, while also defining important boundaries for therapeutic interpretation.

• Tetrahydromagnolol and the Next Wave of CB2 Research

  2026-08-14

  Tetrahydromagnolol offers translational researchers a selective peripheral CB2 pharmacology tool with complementary GPR55 antagonism. When paired with pathway-resolved assays and the TBXA2R–ERM metastasis framework, it can help distinguish receptor engagement from downstream cytoskeletal and inflammatory phenotypes without overstating evidence beyond current studies.

• Entecavir (BMS200475): HBV Mechanism & Use

  2026-08-14

  Entecavir, also known as BMS200475, is a selective HBV DNA polymerase inhibitor that suppresses viral reverse transcription. Its clinical use includes chronic hepatitis B infection therapy, with dose distinctions for nucleos(t)ide-naive, lamivudine-resistant, and decompensated liver disease populations.

8000 records 1/534 page Next 12345 下5页 Last page